Ceva Animal Health invests in new 7,000 m² vaccine manufacturing facility to expand global production capacity

26-Nov-2024 - Ceva Animal Health (Ceva) unveils its latest investment in European vaccine manufacturing, with the construction of a new facility in Hungary, expanding the capacity of Ceva Phylaxia. This development will establish a 7,000 m2 plant in Monor, Hungary withthe most advanced technologies,where Ceva ...

Vaccines from the field?

"Green factories" - vaccines from plants: how does it work?

08-Jul-2024 - Molecular farming is a method that pharmaceutical companies use to transform plants into living bioreactors. The plants are given a new genetic blueprint that enables them to produce substances for medicines and, more recently, vaccines - quickly and cost-effectively, sustainably and safely. ...

Automated, cost-effective production of mRNA vaccines as well as cell and gene therapeutics

“The system will enable automated, component-based, flexible and validatable production”

07-Nov-2023 - mRNA-based vaccines and gene/cell therapeutics open up new possibilities for medical practitioners in the fight against cancer and infectious or hereditary diseases. However, manufacturing these innovative pharmaceuticals is an expensive and time-consuming process. The Fraunhofer RNAuto ...

CureVac and GSK Enter into Pandemic Preparedness Contract with German Government

Five-year contract enables production of up to 80 million vaccine doses at short notice in case of a public health emergency

12-Apr-2022 - CureVac N.V. and GSK announced that they have entered into a contract with the German federal government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany. Following a setup period of a maximum of two years, the contract grants the German federal government ...

Sartorius closes fiscal 2021 with 50 percent growth and a jump in profitability

Number of employees rises by 30 percent to nearly 14,000

27-Jan-2022 - Due to the excellent development of its core business, additional demand generated by the coronavirus pandemic, and several acquisitions, the life science group Sartorius closed fiscal 2021 with exceptionally strong growth and a jump in profitability. According to preliminary figures, the company ...

Merck Collaborates with Innovative Biotech to Support Establishment of First Vaccine Production Facility in Nigeria

15-Dec-2021 - Merck announced that it has signed an agreement with biotechnology company Innovative Biotech (IB) to design the manufacturing process for the first vaccine production facility in Nigeria. “We are committed to expanding access to life-saving and life-enhancing therapies to patients across the ...

Siemens and BioNTech expand their collaboration for global vaccine production

Joint creation of a vaccine production facility in Singapore

24-Jun-2021 - German biotechnology company BioNTech SE, based in Mainz, and Siemens intend to expand their strategic cooperation. The companies plan to intensify their collaboration for the rapid expansion and creation of production capacity for the Covid-19 vaccine. BioNTech has expressed its aim of ...

BioNTech to Establish Regional Headquarters for Southeast Asia and First mRNA Manufacturing Facility in Singapore

Planned state-of-the-art manufacturing site will support global supply of mRNA-based vaccines and therapeutics

12-May-2021 - BioNTech SE announced plans to expand its global footprint to Asia with the establishment of its Regional Headquarters for southeast Asia in Singapore. In addition to selecting Singapore as its future regional headquarters, BioNTech plans to establish a fully integrated mRNA manufacturing ...

Inactivating pathogens using low-energy electrons

Fraunhofer Prize for “Human- and Environment-Centered Technology” for new method of producing vaccines

07-May-2021 - Vaccines are currently a great source of hope for many people, as it is believed they will help to protect society against COVID-19 and pave the way back to a normal life. The current focus is clearly on coronavirus – but vaccines are also fundamental to combating other pathogens. A team of ...

Lonza and Moderna Enter New Agreement to Double Drug Substance Production for COVID-19 Vaccine in Visp

New agreement for three further production lines at Lonza’s site in Visp, Switzerland

29-Apr-2021 - Lonza announced the expansion of its collaboration with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, to manufacture the drug substance for the COVID-19 Vaccine Moderna. The expanded collaboration provides for the installation of three additional drug ...